linjc16/ctgov huggingface dataset:
Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the Effect of different vasodilators as Tadalafil, Sildenafil and pentoxyfylline in In vitro Fertilization. In addition, the thickness of endometrium and pregnancies rates of these women will also be examined. All adverse effects of all drugs will be estimated

Detailed Description
-----------------
A prospective randomized clinical study will be conducted in the IVF clinic of the gynecology department of Beni Suef University Hospital, Beni-Suef, Egypt. The study will These patients will be randomized into four groups. The participants will take drugs starting from the end of menstruation cycle till endometrium reach optimal and then will start progesterone 800 mg daily.

Official Title
-----------------
Effect of Tadalafil, Sildenafil and Pentoxyfylline on Endometrial Thickness and Frozen Embryo Transfer Outcomes

Conditions
-----------------
IVF

Intervention / Treatment
-----------------
* Drug: tadalafil
* Drug: Sildenafil
* Drug: pentoxifylline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women having thawed embryos Exclusion Criteria: hypotension cardiovascular, hepatic, and renal diseases; uncontrolled diabetes mellitus; ovarian cysts; hyperprolactinemia; abnormal thyroid functions; uterine fibroids; patients taking nitrates; endometriosis and adenomyosis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tadalafil<br>tadalafil 10 mg one tablet daily | Drug: tadalafil<br>* tadalafil 10 mg one tablet daily<br>* Other names: cialong;|
| Experimental: pentoxifylline<br>pentoxyfilline 400 mg two tabs daily | Drug: pentoxifylline<br>* pentoxifylline 400 mg two tabs daily<br>* Other names: trental;|
| Experimental: sildenafil<br>sildenafil 20 mg two tablets | Drug: Sildenafil<br>* sildenafil 20 mg two tablets daily<br>* Other names: Respatio;|
| No Intervention: control group.<br>no intervention is given | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endometrial thickness | measured by transvaginal ultrasound | within 16 day of menstruation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate | number of cases positive serum pregnancy test | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tadalafil, Sildenafil, pentoxyfylline, frozen embryo transfer
Impact of an Automatic Alert Device on the Occurrence of Nocturnal Falls in Nursing Home Residents

Study Overview
=================
Brief Summary
-----------------
Impact of an automatic alert device on the occurrence of nocturnal falls in nursing home residents Measurement of the number of nocturnal falls between 8 p.m. and 8 a.m. per registered resident in the 6 months preceding use of the device compared with the number of nocturnal falls in the 6 months after installation of the device.

Official Title
-----------------
Impact of an Automatic Alert Device on the Occurrence of Nocturnal Falls in Nursing Home Residents

Conditions
-----------------
Fall Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Resident of the elderly nursing home (EHPAD LES ORCHIDEES). Repeated nocturnal falls (more than 2 falls at night between 8 p.m. and 8 a.m.) during the last 12 months. Consent of the resident or his legal representative. Signature of informed consent French-speaking resident. Exclusion Criteria: Refusal to participate in the study. Resident exclusive day faller.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of falls | Measurement of the number of nocturnal falls between 8 p.m. and 8 a.m. per registered resident in the 6 months preceding use of the device compared with the number of nocturnal falls in the 6 months after installation of the device. | 6 month preceding and 6 month after |
The Impact of Covid 19 Pandemic on Ureteric Stents Complications.

Study Overview
=================
Brief Summary
-----------------
The pandemic of coronavirus disease 2019 (COVID-19) has serious implications on urology practice and raises particular questions for urologists about the management of different conditions. It was recommended to cancel most of the elective urological surgeries. (1) The least invasive intervention modalities that can be completed in local or regional anesthesia will serve the best interest of patients and urologists. 10 14 Endoscopic surgery is considered relatively safe.(2) After end of pandemic we facing complication of this era, one of most common complication was JJ stents complications as most of patient and doctors prefers to defer most of elective management by just JJ insertion and postpone definitive treatment. (3) In this study we discuss retrospectively the complication of JJ stenting during Covid 19 pandemic.

Detailed Description
-----------------
Type of the study: retrospective clinical study Study Setting: Qena University Hospital 3- Study subjects: a. Inclusion criteria: all patients performing JJ stent placement during Covid 19 pandemics b. Exclusion criteria: Patients refuse to participate in this study c. Sample Size Calculation: all patients performing JJ stent placement from March 2020 to December 2021 Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …): Medical history Complete physical examination. All patents presented was investigated by Abdominal U.S Plain X Ray Non contrast CT Serum Creatinine Urine Analysis Research outcome measures: Primary (main): determine effect of urological malpractice during Covid 19 on patient complications Secondary (subsidiary): determine JJ stent complications during Covid 19 pandemics

Official Title
-----------------
The Impact of Covid 19 Pandemic on Ureteric Stents Complications.

Conditions
-----------------
Determine Effect of Urological Malpractice During Covid 19 on Patient Complications

Intervention / Treatment
-----------------
* Other: JJ urological stents


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients performing JJ stent placement during Covid 19 pandemics Exclusion Criteria: Patients refuse to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: JJ urological stents|recording complications of JJ stents during COVID19 pandemics|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| jj stents complications during covid 19 pandimics | determine effect of urological malpractice during Covid 19 on patient complications | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urological stents , COVID19
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: How much effect AP-306 has assessed by blood phosphorus lowering; How safe and tolerable AP-306 is. Participants will receive either following treatments: AP-306, and Sevelamer carbonate.

Official Title
-----------------
A Phase 2, Randomized, Open-Label, Active-Controlled, Multicenter Study to Evaluate the Safety and Serum Phosphorus Lowering Effect of AP-306 in Chronic Kidney Disease Patients Receiving Maintenance Hemodialysis With Hyperphosphatemia

Conditions
-----------------
Chronic Kidney Diseases, Hyperphosphatemia

Intervention / Treatment
-----------------
* Drug: AP-306
* Drug: Sevelamer Carbonate


Participation Criteria
=================
Eligibility Criteria
-----------------
Important Inclusion Criteria: On a stable hemodialysis regimen at a frequency of three times per week for at least 12 weeks prior to the screening visit Dialysis sufficiency SpKt/V ≥ 1.2 at the screening visit or any documented result within 12 weeks prior to the screening visit Serum phosphorus within the trial-required range Important Exclusion Criteria: Pregnant or breastfeeding Any history of kidney transplant Any history of a parathyroid intervention Any clinically significant GI disorders within 4 weeks prior to the screening visit Hospitalization for cardiac or cerebrovascular disease within 24 weeks prior to the screening visit Hospitalization for cardiac or cerebrovascular disease within 24 weeks prior to the screening visit Documented history of hypersensitivity or allergic reactions to any of the excipients used by AP-306, or history of hypersensitivity or allergic reactions or intolerant to sevelamer carbonate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AP-306<br> | Drug: AP-306<br>* A blood phosphorus lowering drug with a novel mechanism<br>|
| Active Comparator: Sevelamer Carbonate<br> | Drug: Sevelamer Carbonate<br>* A phosphate binder<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the efficacy of AP-306 assessed by serum phosphorus lowering | The change in serum phosphorus level from the baseline to the end of treatment | 12 weeks |
18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

Study Overview
=================
Brief Summary
-----------------
This is a open-label, one-arm, multicenter study aimed to explore the efficacy and safety of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

Official Title
-----------------
Prospective Study of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

Conditions
-----------------
18F-HER2 PET

Intervention / Treatment
-----------------
* Diagnostic Test: 18F-HER2 PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent document must be signed. Aged 30-80 years old, both genders. Patients with locally advanced or advanced urothelial carcinoma Patients plan to undergo anti HER2 treatment. Exclusion Criteria: Subjects with active malignancies other than urothelial carcinoma within 5 years should be excluded. Patients with severe liver, kidney, and hematopoietic diseases Patients with other mental disorders or primary emotional disorders Those who are unable to understand, comply with the research protocol, or sign an informed consent form PET imaging Contraindication (including pregnant women, lactating women, women of childbearing age who have a recent fertility plan, etc.) Individuals who are allergic to imaging agents Hypoglycemic reactions, severe pain, etc. cannot be accompanied by PET scans

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 18F-HER2 PET<br> | Diagnostic Test: 18F-HER2 PET<br>* 18F-HER2 PET<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma |  | up to 2 years |
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

Study Overview
=================
Brief Summary
-----------------
To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration To study pharmacokinetic, side effect of low dose Emicizumab

Detailed Description
-----------------
To compare outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration using ABR, AJBR and HJHS, HaemoQoL To study pharmacokinetic, side effect and effectiveness of low dose Emicizumab

Official Title
-----------------
Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

Conditions
-----------------
Severe Hemophilia A Without Inhibitor, Joint Bleed

Intervention / Treatment
-----------------
* Drug: Emicizumab, HEMLIBRA®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe or moderate Hemophilia A with baseline FVIII:C of <3 IU/dl or severe bleeding phenotype Receiving low dose FVIII prophylaxis for at least 6 months Exclusion Criteria: Detectable FVIII inhibitor at screening Detectable FVIII inhibitor at screening Having other underlying diseases: Juvenile rheumatoid arthritis, metabolic bone diseases, or other conditions mimicking or causing joint diseases

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: low dose emicizumab<br>2 mg per kilograms per dose in first month, loading every 2 weeks then every 4 weeks | Drug: Emicizumab, HEMLIBRA®<br>* low dose<br>* Other names: emicizumab-kxwh;|
| No Intervention: low dose factor VIII prophylaxis<br>factor VIII prophylaxis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| spontaneous and traumatic bleeding rate | Using Annualized bleeding rate (ABR) | 6 months after start low dose emicizumab as secondary prophylaxis treatment | 
| treated spontaneous bleeds, treated joint bleeds | Using Annualized joint bleeding rate (AJBR) | 6 months after start low dose emicizumab as secondary prophylaxis treatment | 
| The function of the knee, elbow, and ankle joints | Using Hemophilia Joint Health Score (HJHS) | 6 months after start low dose emicizumab as secondary prophylaxis treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
emicizumab, hemophilia A
Changes of Optical Quality During the Peak of the Covid-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

Detailed Description
-----------------
Participants with healthy corneas admitted to Tianjin Eye Hospital from November 25 to January 20, 2022 were followed up . At the end of the follow-up, the investigators recorded in detail whether the patients had undergone real-time reverse transcriptase polymerase chain reaction (covid-19 RT-PCR tests) testing, testing time and results. The presence of PCR-positive during follow-up is considered to be covid-19 infection; PCR-Negative and no symptoms of infection during the follow-up period are considered not infected; participants with symptoms but no PCR test were excluded from the study.Participants were divided into three groups according to the RT-PCR results and the presence or absence of symptoms of infection during follow-up. pentacam (Pentacam HR, Oculus, Wetzlar, Germany) was performed during follow-up and the results were recorded,and the data was statistically managed and compared.

Official Title
-----------------
Changes of Optical Quality During the Peak of the Covid-19 Pandemic From November 2022 to January 2023 in China

Conditions
-----------------
Corneal Wavefront Aberration, SARS-CoV-2

Participation Criteria
=================
Eligibility Criteria
-----------------
Included Criteria Best corrected visual acuity (BCVA) ≥ 20/20; No other eye diseases except myopia and astigmatism; The cornea was transparent, and there was no cloud or pannus; No clinical manifestation of Eye disease or systemic disease; Exclusion Criteria: corneal disease; ocular trauma; Pregnant and lactating women;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 32 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control Group<br>unifected with SARS-CoV-2 during follow-up | |
| Group A<br>uninfected at the first visit, have been infected at the second visit | |
| group B<br>have been infected at twice visit | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The value of cornea aberration | The value of aberration data from pentacam during follow-up were compared, including coma, spherical aberration, defocus, and astigmatism | 1 months | 
| The value of cornea backscatter | The value of cornea backscatter from pentacam during follow-up were compared, including anterior layer，central layer and posterior | 1 months | 
| The value of cornea thickness | The value of cornea thickness from pentacam during follow-up were compared, includig the thinnest point, apex of the cornea. | 1 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
optical quality
Checklist for AI in Medical Imaging (CLAIM) Consensus Panel

Study Overview
=================
Brief Summary
-----------------
The investigators will revise the Checklist for AI in Medical Imaging (CLAIM) guideline using Delphi consensus methods. An international panel of physicians, researchers, and journal editors with expertise in AI in medical imaging -- including radiology, pathology, dermatology, GI endoscopy, and ophthalmology -- will complete up to 3 web-based surveys. Participants who complete all survey rounds will be credited as contributors on resulting publications.

Detailed Description
-----------------
The survey will be administered in collaboration with: Anthony A. Gatti, PhD (Stanford University) Michail E. Klontzas, MD, PhD (University of Crete School of Medicine) * Linda Moy, MD (New York University Grossman School of Medicine) John Mongan, MD, PhD (University of California San Francisco) Seong Ho Park, MD, PhD (University of Ulsan College of Medicine) Ali S. Tejani, MD (University of Texas Southwestern Medical School) (*) Survey administrator

Official Title
-----------------
Checklist for AI in Medical Imaging (CLAIM) Consensus Panel

Conditions
-----------------
Artificial Intelligence, Machine Learning, Diagnostic Imaging

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: More than 70 invited panelists -- physicians, AI researchers, and journal editors -- have agreed to participate in the surveys. Those who participate in all rounds of the survey will be named as contributors in any resulting publications Exclusion Criteria: Non physicians, AI researchers and journal editors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Revise the Checklist for AI in Medicine Imaging (CLAIM) guideline | potential revision of the CLAIM guidelines through Delphi consensus process. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Checklist for AI in Medical Imaging (CLAIM), Reporting guideline, Delphi consensus method, Survey